Skip to main content

Table 2 Treatment history

From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Treatment history, n (%)PD-L1 TC ≥ 25%
(n = 132a)
PD-L1 TC < 25%
(n = 264a)
Total (N = 412)
Palliative surgical interventions44 (33.3)74 (28.0)123 (29.9)
Radiotherapy43 (32.6)63 (23.9)113 (27.4)
Chemoradiation therapy1 (0.8)0 (0.0)1 (0.2)
Line of chemotherapy, n132264412
 1st69 (52.3)159 (60.2)238 (57.8)
 2nd24 (18.2)55 (20.8)84 (20.4)
  ≥ 3rd8 (6.1)28 (10.6)42 (10.2)
Type of first-line chemotherapy, n77177266
 Cetuximab38 (49.4)91 (51.4)132 (49.6)
 Cisplatin41 (53.2)71 (40.1)119 (44.7)
 Carboplatin15 (19.5)64 (36.2)84 (31.6)
 Paclitaxel10 (13.0)56 (31.6)67 (25.2)
 Docetaxel18 (23.4)22 (12.4)43 (16.2)
 5-Fluorouracil35 (45.5)56 (31.6)97 (36.5)
Type of second-line chemotherapy256090
 Cetuximab8 (32.0)21 (35.0)30 (33.3)
 Cisplatin1 (4.0)4 (6.7)5 (5.6)
 Carboplatin6 (24.0)13 (21.7)20 (22.2)
 Paclitaxel5 (20.0)20 (33.3)25 (27.8)
 Docetaxel7 (28.0)10 (16.7)18 (20.0)
 5-Fluorouracil5 (20.0)5 (8.3)10 (11.1)
  1. aPatients with PD-L1 result N = 396
  2. PD-L1 programmed cell death-ligand 1, TC tumor cell